Within the ER+/HER2– breast cancer samples, we show for the first time that unsupervised hierarchical clustering resulted in the distinction of tumours with a preferentially activated (group A) and not activated (group N) profile categorising patients with differential adjuvant tamoxifen benefit. The gene discussed is ERBB2; the disease is neoplasm.